Every Wednesday, NeurologyLive®'s NeuroVoices series features in-depth, exclusive conversations with a wide variety of experts in the care and management of patients with neurologic diseases about a range of topics in clinical care and therapeutic development.
NeuroVoices: Benzi Kluger, MD, MS, on the Expansion and Growth of Neuropalliative Care
November 23rd 2022The president of the International Neuropalliative Care Society provided perspective on the growth of the field of neuropalliative care, the organization’s role, and how clinicians are overcoming current barriers in place.
NeuroVoices: Timothy Miller, MD, PhD, on the Impact of Tofersen, Antisense Therapeutics in ALS
November 16th 2022The codirector of the ALS Center at Washington University School of Medicine in St. Louis provided perspective on the phase 3 VALOR findings of tofersen, an antisense agent currently under review to treat SOD1-mutated ALS.
NeuroVoices: Wayne Feng, MD, FAHA, on Changing the Approach to Poststroke Neuromuscular Symptoms
October 12th 2022The division chief of stroke and vascular neurology at Duke Health discussed how clinicians have typically treated poststroke motor symptoms and how technology is expanding these capabilities.
NeuroVoices: Thomas M. Wisniewski, MD, on Raising Awareness for World Alzheimer’s Day
September 21st 2022The director of NYU Langone’s Alzheimer’s Disease Research Center and Center for Cognitive Neurology provided perspective on raising awareness for World Alzheimer’s Day and the ongoing challenges patients with the disease face.
NeuroVoices: Lynn Bekris, PhD, on sTREM2 and GFAP to Differentiate Cognitive Status, Trajectory
September 7th 2022The molecular biologist at the Cleveland Clinic Lerner Research Institute provided commentary on how certain activity markers may help understand immune response differences in Alzheimer disease and related dementias.
NeuroVoices: Lindsey Lee Lair, MD, on the Phase 3 RESILIENT Trial of Taldefgropeb Alfa in SMA
July 20th 2022The vice president of clinical development at Biohaven provided insight on a new phase 3 study assessing a muscle-targeted agent as an adjunct therapy to currently approved spinal muscular atrophy medications.
NeuroVoices: Francois Bethoux, MD, on Innovating MS Rehabilitation With the EksoNR Exoskeleton
July 6th 2022The chair of Cleveland Clinic’s Department of Physical Medicine discussed a new rehabilitative approach using a robotic exoskeleton to improve fatigue and gait in patients with multiple sclerosis.
NeuroVoices: Jens Kuhle, MD, on Evobrutinib’s Association With Neurofilament Light Levels
June 8th 2022The head of the MS Center at the University of Basel discussed an analysis presented at CMSC’s Annual Meeting, focusing on the effects of BTK inhibitor evobrutinib on neurofilament light levels.
NeuroVoices: Michael Sughrue, MD, on Using Machine Learning to Build a Better Brain Map
June 1st 2022The founder and chief medical officer of Omniscient Neurotechnology discussed how the use of machine learning and big data will be critical in revolutionizing our understanding of the brain and mental illnesses.
NeuroVoices: Michael Sughrue, MD, on the Future of Brain Mapping and Utilizing Advanced Technology
May 25th 2022The founder and chief medical officer of Omniscient Neurotechnology provided commentary on expanding the brain map, the use of advanced technology, and the need to familiarize clinicians with connectomics.
NeuroVoices: Mark Lew, MD, on Exploring Reflex Tears as a Biomarker for Parkinson Disease
April 27th 2022The director of the Division of Movement Disorders at the USC Keck School of Medicine discussed the phenomenon behind reflex tears and whether they can serve as a valuable biomarker for Parkinson disease.
NeuroVoices: Neal Hermanowicz, MD, on Isolation’s Impact on Patient Burden in Parkinson Disease
April 20th 2022The neurologist at Christus St Vincent Health System discussed a recently conducted survey on the effects of social isolation and the need to keep patients with Parkinson disease socially connected.